Market Overview

Zohydro Gains Massachusetts Approval, Acts As Minor Catalyst For Zogenix

Share:

Zohydro in March was blocked by regulators in the state of Massachusetts.

On Monday, however, Zohydro was included back onto the MassHealth drug list, with “prior authorization." According to Masshealth, "The updates to the List are effective immediately, unless otherwise specified. For medications that have new PA requirements."

Zogenix (NASDAQ: ZGNX), moved higher by 11.1 percent in Tuesdays pre-market trading session, but he optimism faded in Tuesday's trading session.

Difei Yang from R.F. Lafferty & Co stated, "The impact from Massachusetts approval of Zohydro won't add much in terms of incremental revenue for Zygonex. The Massachusetts approval was a minor catalyst."

Zogenix traded recently at $1.33, down 0.75 percent.

 

Related Articles (ZGNX)

View Comments and Join the Discussion!

Posted-In: Difei Yang R.F. Lafferty & CoNews Legal

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com